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Inorganic arsenic (arsenite, arsenate) is a 
naturally occurring toxicant and carcinogen 
(International Agency for Research on Cancer 
2004; National Toxicology Program 2002) 
that contaminates groundwater supply systems 
in countries around the world (Smedley and 
Kinniburgh 2002). In the United States, arse-
nic levels in drinking water > 10 µg/L—the 
U.S. Environmental Protection Agency (EPA) 
maximum contaminant level—disproportion-
ately affect small communities in the West, 
Midwest, and Northeast regions (Focazio et al. 
2000; U.S. EPA 2001). Flour and rice also con-
tain inorganic arsenic, particularly if grown or 
cooked in areas with arsenic contamination 
in soil and water (Del Razo et al. 2002). The 
metabolism of inorganic arsenic in the human 
body results in methylarsonate (MA) and dim-
ethylarsinate (DMA), which are excreted in 
urine together with unchanged inorganic arse-
nic (Aposhian and Aposhian 2006; Cullen and 
Reimer 1989). Seafood is a source of organic 
arsenic compounds (arsenobetaine, arsenosug-
ars, arsenolipids) that have no or low toxicity 
compared with inorganic arsenic (Francesconi 
and Kuehnelt 2004).
In populations with low seafood intake, 
total urine arsenic and the sum of inorganic 
arsenic and methylated (MA and DMA) urine 
arsenic species are established biomarkers that 
integrate inorganic arsenic exposure from mul-
tiple sources (Calderon et al. 1999; Francesconi 
and Kuehnelt 2004; Hughes 2006; National 
Research Council 1999). The proportion of 
arsenic species that is excreted as inorganic arse-
nic, MA, or DMA also provides information 
on the metabolism of inorganic arsenic in the 
human body. The arsenic species excretion pat-
tern in human urine is approximately 10–20% 
inorganic arsenic, 10–20% MA, and 60–80% 
DMA, with substantial variation among indi-
viduals (Chiou et al. 1997; Del Razo et al. 
1997; Hopenhayn-Rich et al. 1996b; Vahter 
2000). Individual arsenic excretion patterns, 
on the other hand, were fairly constant over 
time in studies of up to 1 year of follow-up 
(Concha et al. 2002; Steinmaus et al. 2005b). 
Because a higher proportion of MA in urine has 
been associated with an increased risk of cancer 
(Chen et al. 2003a, 2003b, 2005; Hsueh et al. 
1997; Maki-Paakkanen et al. 1998; Steinmaus 
et al. 2006; Yu et al. 2000) and cardiovascular 
(Tseng et al. 2005; Wu et al. 2006) outcomes, 
there is substantial interest in characterizing the 
long-term arsenic species excretion patterns, 
especially for MA.
The objective of this study was to conduct 
an initial assessment of arsenic exposure and 
excretion pattern, as measured by total urine 
arsenic and urine arsenic species, in American 
Indians from Arizona, Oklahoma, and North 
and South Dakota who participated in the 
Strong Heart Study, a population-based pro-
spective cohort study funded by the National 
Heart, Lung, and Blood Institute (Lee et al. 
1990; Strong Heart Study 2008). On the basis 
of arsenic concentrations measured in public 
drinking water systems in the Strong Heart 
Study communities, we expected arsenic expo-
sure levels to be higher in Arizona, intermediate 
in the Dakotas, and lower in Oklahoma. Given 
dietary patterns in the study communities 
(Stang et al. 2005), we expected arsenobetaine 
concentrations, a marker of seafood arseni-
cals, to be very low. Using three urine samples 
for each participant, we also assessed arsenic 
exposure and excretion patterns over a 10-year 
period and the feasibility of measuring arsenic 
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Ba c k g r o u n d: Arsenic exposure in drinking water disproportionately affects small communities in 
some U.S. regions, including American Indian communities. In U.S. adults with no seafood intake, 
median total urine arsenic is 3.4 µg/L.
oB j e c t i v e: We evaluated arsenic exposure and excretion patterns using urine samples collected over 
10 years in a random sample of American Indians from Arizona, Oklahoma, and North and South 
Dakota who participated in a cohort study from 1989 to 1999.
Me t h o d s : We measured total urine arsenic and arsenic species [inorganic arsenic (arsenite and arsen­
ate), methylarsonate (MA), dimethylarsinate (DMA), and arsenobetaine] concentrations in 60 partici­
pants (three urine samples each, for a total of 180 urine samples) using inductively coupled plasma/
mass spectrometry (ICPMS) and high­performance liquid chromatography/ICPMS, respectively.
re s u l t s: Median (10th, 90th percentiles) urine concentration for the sum of inorganic arsenic, 
MA, and DMA at baseline was 7.2 (3.1, 16.9) µg/g creatinine; the median was higher in Arizona 
(12.5 µg/g), intermediate in the Dakotas (9.1 µg/g), and lower in Oklahoma (4.4 µg/g). The mean 
percentage distribution of arsenic species over the sum of inorganic and methylated species was 
10.6% for inorganic arsenic, 18.4% for MA, and 70.9% for DMA. The intraclass correlation coef­
ficient for three repeated arsenic measurements over a 10­year period was 0.80 for the sum of inor­
ganic and methylated species and 0.64, 0.80, and 0.77 for percent inorganic arsenic, percent MA, 
and percent DMA, respectively.
co n c l u s i o n s: This study found low to moderate inorganic arsenic exposure and confirmed long­
term constancy in arsenic exposure and urine excretion patterns in American Indians from three 
U.S. regions over a 10­year period. Our findings support the feasibility of analyzing arsenic species 
in large population­based studies with stored urine samples.
key w o r d s : American Indians, analytical chemistry, arsenic, arsenic species, arsenobetaine, exposure 
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species in long-term stored urine samples frozen 
at –70°C.
Materials and Methods
Study population. The Strong Heart Study was 
designed to investigate cardiovascular disease 
and its risk factors in 13 American Indian com-
munities located in Arizona, Oklahoma, and 
North and South Dakota (Howard et al. 1999; 
Lee et al. 1990). From 1989 to 1991, enrolled 
tribal members 45–74 years of age who were 
living in those communities were invited to par-
ticipate. The aim was to recruit approximately 
1,500 participants per region. In Arizona and 
Oklahoma, every eligible person was invited to 
participate, in person or by letter. In North and 
South Dakota, a cluster sampling technique 
was used (Lee et al. 1990). A total of 4,549 
participants were recruited in 1989–1991 for a 
baseline visit and invited to participate in sub-
sequent visits in 1993–1994 and 1998–1999. 
The participation rates were 62% at baseline 
and 89% and 88% for surviving participants 
at visits 2 and 3, respectively. All study visits 
included a questionnaire, a physical examina-
tion, and biological specimen collection. The 
Strong Heart Study protocol and consent form 
were approved by the Institutional Indian 
Health Service Review Boards and by the par-
ticipating Indian communities. Informed con-
sent was obtained from all participants. For the 
present study, we randomly selected 60 Strong 
Heart Study participants (20 from Arizona, 20 
from Oklahoma, and 20 from the Dakotas) 
among those for whom we had stored urine 
samples from the three study visits (n = 3,197). 
Participants’ characteristics (age, sex, body mass 
index, smoking, and alcohol use) in the pres-
ent study were comparable to the overall study 
population (Table 1).
Arsenic determinations. Spot urine samples 
were collected in polypropylene tubes, frozen 
within 1–2 hr of collection, shipped in dry ice, 
and stored from 8 to 18 years at –70°C in the 
Penn Medical Laboratory, MedStar Research 
Institute (Washington, DC, USA). The freezers 
have been operating under a strict quality con-
trol system to guarantee secure sample storage. 
For arsenic analyses, urine samples were thawed 
in August 2007, and up to 1.0 mL was trans-
ferred to a small vial, transported on dry ice to 
the Trace Element Laboratory, Graz University, 
Austria, and stored at –80°C until analysis. 
Urine samples were frozen for an average of 
13 years (range, 8–18 years) before analysis.
We measured total urine arsenic concentra-
tions (expressed on an elemental basis) using 
inductively coupled plasma/mass spectrometry 
(ICPMS). The limit of quantification for total 
urine arsenic was 0.1 µg/L. We checked meas-
urement accuracy with 1+19 diluted human 
urine no. 18 from Japan’s National Institute 
of Environmental Studies (Tsukuba, Japan) 
(e.g., 0.5 mL urine + 9.5 mL water). The meas-
ured mean (± SD) total arsenic concentration 
of 144 ± 4 µg/L (n = 19) was in agreement with 
the certified concentration of 137 ± 11 µg/L. 
Total arsenic concentrations exceeded the limit 
of quantification in all samples.
Urine concentrations of arsenite, arsenate, 
MA, and DMA (expressed on an elemental 
basis) were measured using high-performance 
liquid chromatography/vapor generation ICPMS 
(Lindberg et al. 2006). The limits of quantifica-
tion were 0.1 µg/L for arsenite and 0.5 µg/L for 
arsenate, MA, and DMA. Arsenite and arsenate 
were below the limit of quantification in 2 (1%) 
and 126 (70%) samples, respectively. MA and 
DMA exceeded the limit of quantification in all 
samples. The interassay coefficients of variation 
for an in-house reference urine sample for arsen-
ite, arsenate, MA, and DMA were 3.8%, 4.5%, 
4.3%, and 1.9%, respectively (n = 18). We did 
not detect thio-DMA, an arsenic species that has 
been related to arsenosugar exposure (Hansen 
et al. 2003; Raml et al. 2005) and to high arsenic 
exposure in Bangladesh (Raml et al. 2007), in 
any of the study samples.
We measured urine arsenobetaine concen-
trations using cation-exchange chromatogra-
phy on a Zorbax 300 SCX column (4.6 mm 
inner diameter × 250 mm; Agilent, Waldbronn, 
Germany) operated at 30°C. The mobile phase 
was 10 mM pyridine (pH 2.3, adjusted with 
formic acid) at a flow rate of 1.5 mL/min. We 
injected 20 µL of sample. The limit of quantifi-
cation for urine arsenobetaine was 0.5 µg/L. We 
checked the accuracy of the measurements with 
1+9 diluted human urine no. 18. The mean 
(± SD) measured value for arsenobetaine was 
68 ± 2 µg/L (n = 18), in agreement with the 
certified concentration of 69 ± 12. Ninety-six 
(53%) samples had concentrations below the 
limit of quantification, reflecting infrequent sea-
food intake in the study population. The median 
(10th–90th percentiles) of urine arsenobetaine 
was 0.5 µg/L creatinine (< 0.5–137) [0.5 µg/g 
(< 0.5–6.1)]. Urine arsenobetaine concentra-
tions were similarly low by region and other 
participant characteristics (data not shown).
Other variables. Baseline information on 
sociodemographic data (age, sex, study region), 
smoking history, alcohol use, and body mass 
index (kilograms per square meter) were 
obtained from the Strong Heart Study ques-
tionnaires and physical examinations (Howard 
et al. 1999; Lee et al. 1990). Urine creatinine 
was measured at the laboratory of the National 
Institute of Diabetes and Digestive and Kidney 
Diseases Epidemiology and Clinical Research 
Branch (Phoenix, AZ, USA) by an automated 
alkaline picrate methodology run on a rapid 
flow analyzer (Lee et al. 1990). To account for 
urine dilution in spot urine samples, we divided 
urine arsenic (micrograms per liter) by urine 
creatinine (grams per liter) and expressed the 
concentrations of total urine arsenic and its spe-
cies in terms of micrograms per gram creatinine.
Statistical analyses. Because the limit of 
quantification was different for arsenite and 
arsenate and 70% of participants had arsen-
ate concentrations below the limit of quanti-
fication, we used a bivariate Tobit multilevel 
model (Tobin 1958) to impute these values 
in participants with arsenite or arsenate levels 
below the limit of quantification. The bivariate 
Tobit multilevel model had random participant 
and region-specific intercepts and used total 
urine arsenic concentrations as an explanatory 
variable. Arsenite and arsenate concentrations 
in participants with values below the limit of 
quantification were imputed as the median of 
the participant-specific posterior distribution 
derived from the bivariate Tobit multilevel 
model. For arsenite, the posterior distribution 
median was 0.08 µg/L for each of the two sam-
ples below the limit of quantification. For arsen-
ate, the median (10th–90th percentiles) of the 
posterior distribution medians for the 126 urine 
samples below the limit of quantification was 
0.13 µg/L (0.07–0.26). We calculated urine 
inorganic arsenic concentration as the sum of 
arsenite and arsenate concentrations.
Because urine concentrations of total arse-
nic and its species were right-skewed, we used 
medians and 10th and 90th percentiles to 
describe their distributions. To evaluate varia-
tion in arsenic excretion patterns, we calculated 
the percentages of inorganic arsenic, MA, and 
Table 1. Strong Heart Study participants’ characteristics at baseline.
Characteristic
Arizona Oklahoma Dakotas
Overall 
(n = 1,500)
Present study 
(n = 20) p-Valuea
Overall 
(n = 1,527)
Present study 
(n = 20) p-Valuea
Overall 
(n = 1,522)
Present study 
(n = 20) p-Valuea
Age [years (mean ± SD)] 56 ± 8 52 ± 8 0.03 57 ± 8   55 ± 8 0.58 56 ± 8 54 ± 6 0.23
Male (%) 36 45 0.48 42   35 0.65 43 50 0.65
Body mass index [kg/m2 (mean ± SD)] 32 ± 7 35 ± 6 0.06 31 ± 6   31 ± 7 1.00 29 ± 6 30 ± 4 0.46
Current cigarette smoking (%) 19 30 0.21 34   25 0.48 48 60 0.37
Current alcohol use (%) 40 35 0.82 37   45 0.49 48 60 0.37
aBased on Student’s t-test and Fisher’s exact test for means and percentages, respectively.Navas-Acien et al.
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DMA over the sum of inorganic and methyl-
ated species (%iAs, %MA, and %DMA). These 
percentages were normally distributed; we 
describe them using means ± SDs.
To evaluate the determinants of biomarkers 
of inorganic arsenic exposure at baseline and 
their trajectories over time, we used mixed lin-
ear models for change for log-transformed total 
arsenic, inorganic arsenic, MA, and DMA con-
centrations in urine. We used study region, sex, 
age, body mass index, smoking status, and alco-
hol consumption as fixed effects (explanatory 
variables). From these models, we estimated the 
ratios of the geometric means of baseline urine 
arsenic concentrations and of their annual rates 
of change comparing different categories of the 
explanatory variables. In sensitivity analyses, we 
also ran generalized estimated equation (GEE) 
models (Liang and Zeger 1986), overall and 
stratified by region. Findings were similar (data 
not shown).
We also used mixed linear models for 
change to model the %MA over the sum of 
inorganic and methylated arsenic species and 
to estimate the mean differences in baseline 
%MA and in its annual rate of change compar-
ing different categories of study region, sex, 
age, body mass index, smoking status, and 
alcohol use. In sensitivity analyses, we also ran 
GEE models (Liang and Zeger 1986), overall 
and stratified by region. Findings were similar 
(data not shown).
We calculated intraclass correlation coef-
ficients (ICCs) to describe the extent of within-
individual compared with between-individual 
variability over time. A high ICC (close to 1) 
indicates that the within-individual variability 
is relatively small compared with the between-
individual variability and that biomarkers of 
arsenic exposure and metabolism are relatively 
stable for an individual compared with between-
individual variability. We performed all statisti-
cal analyses using the program R (R Project for 
Statistical Computing, Vienna, Austria).
Results
Participant characteristics. The mean (± SD) 
age of study participants was 54 ± 8 years, and 
43% were men, with small differences across 
regions (Table 1). Similar to the overall Strong 
Heart Study population, participants from 
Arizona had higher body mass index compared 
with participants from Oklahoma and the 
Dakotas, and participants from the Dakotas 
were more likely to be current smokers and to 
use alcohol compared with participants from 
Arizona and Oklahoma.
Arsenic concentrations. Median (10th–90th 
percentiles) concentrations for total arsenic and 
for the sum of inorganic and methylated arsenic 
Table 2. Urine arsenic concentration (total and species) and percentage of urine arsenic species over 
the sum of inorganic and methylated species (ΣAs).
Measure
Visit 1 (1989–1991) 
(n = 60)
Visit 2 (1993–1995) 
(n = 60)
Visit 3 (1998–1999) 
(n = 60)
Urine concentration (µg/g creatinine) [median (10th, 90th percentiles)]
Total arsenic  10.5 (4.0–27.8) 8.6 (4.0–18.0) 8.9 (4.2–26.7)
ΣAs (iAs + MA + DMA) 7.2 (3.1–16.9) 6.7 (2.9–14.4) 7.1 (3.5–20.4)
iAs (arsenite + arsenate) 0.6 (0.3–2.3) 0.6 (0.3–1.6) 0.6 (0.3–1.9)
MA 1.3 (0.5–3.6) 1.1 (0.5–2.0) 1.1 (0.5–3.3)
DMA 5.0 (2.2–12.8) 4.8 (2.2–11.4) 4.9 (2.7–15.0)
Arsenobetaine 0.5 (< 0.5–6.1) 0.5 (< 0.5–2.1)  < 0.5 (< 0.5–4.3)
Percentage of ΣAs (mean ± SD)
%iAs 10.6 ± 5.2 10.4 ± 4.6 8.9 ± 4.1
%MA 18.4 ± 5.8 16.3 ± 5.0 16.2 ± 5.1
%DMA 70.9 ± 10.0 73.4 ± 8.5 74.9 ± 8.0
iAs (arsenite, arsenate), inorganic arsenic. 
Table 3. Baseline urine arsenic concentrations and excretion pattern by participant characteristics.
Characteristic No.
Total arsenic 
(µg/g creatinine)a
ΣAs 
(µg/g creatinine)a %iAsb %MAb %DMAb
Overall 60 10.5 (4.4–27.8) 7.2 (3.1–16.9) 10.6 ± 5.2 18.4 ± 5.8 70.9 ± 10.0 
Region
Arizona 20 16.9 (8.1–29.2) 12.5 (6.4–17.4) 12.4 ± 7.2 19.4 ± 5.8 68.3 ± 12.1
Oklahoma 20 6.4 (3.9–15.2) 4.4 (3.0–7.7) 8.6 ± 2.3 15.4 ± 5.2 76.0 ± 6.6
Dakotas 20 10.6 (3.8–48.1) 9.1 (2.7–30.2) 10.9 ± 4.3 20.5 ± 5.4 68.6 ± 12.1
Sex
Female 34 10.6 (3.9–37.5) 6.6 (3.9–37.5) 8.4 ± 2.9 15.2 ± 3.9 76.3 ± 10.2
Male 26 10.1 (4.2–18.8) 7.8 (3.2–15.4) 13.4 ± 6.2 22.6 ± 5.1 64.0 ± 5.7
Age (years)
45–54 35 11.3 (4.8–26.3) 7.5 (3.1–17.0) 11.7 ± 5.8 19.2 ± 6.1 69.1 ± 10.9
55–75 25 8.2 (4.0–24.4) 6.2 (3.2–14.9) 9.2 ± 3.7 17.3 ± 5.2 73.5 ± 8.1
Body mass index
< 30 kg/m2 24 8.7 (4.2–18.6) 5.9 (3.2–15.4) 10.8 ± 5.6 19.9 ± 5.9 69.3 ± 10.5
≥ 30 36 12.3 (4.0–35.1) 7.8 (3.3–18.3) 10.5 ± 5.0 17.4 ± 5.5 72.1 ± 9.7
Smoking
Never 18 8.6 (3.5–21.5) 4.6 (2.9–12.8) 8.5 ± 2.9 15.8 ± 5.2 75.7 ± 7.2
Former 19 13.9 (6.0–42.2) 11.5 (4.5–28.1) 9.9 ± 3.2 16.9 ± 4.8 73.2 ± 7.0
Current 23 10.5 (5.9–19.3) 7.5 (3.3–15.5) 12.9 ± 6.9 21.8 ± 5.5 65.4 ± 11.6
Alcohol
Never 9 7.5 (3.5–16.1) 4.4 (2.9–9.2) 8.4 ± 2.6 14.6 ± 4.0 77.0 ± 6.0
Former 23 10.5 (5.7–38.7) 7.5 (4.0–19.2) 10.1 ± 3.8 18.2 ± 5.5 71.7 ± 8.5
Current 28 11.0 (4.2–23.3) 8.4 (3.2–16.4) 11.8 ± 6.4 19.8 ± 6.0 68.4 ± 11.5
Abbreviations: iAs, inorganic arsenic; ΣAs, sum of inorganic arsenic, MA, and DMA. Urine arsenic excretion pattern is 
estimated as the percentage over the sum of iAs (arsenite, arsenate) and methylated species (MA, DMA).
aMedian (10th–90th percentiles). bMean ± SD.
Figure 1. Sum of inorganic (arsenite and arsenate) and methylated (MA and DMA) species (µg/g creatinine) by study visit and region: (A) Arizona, (B) Oklahoma, 
(C) Dakotas. Blue lines connect the levels for each participant; black lines represent the median for each region. 
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species at baseline (visit 1) were 10.5 µg/g crea-
tinine (4.0–27.8) [12.5 µg/L (4.3–42.7)] and 
7.2 µg/g (3.1–16.9) [9.8 µg/L (2.8–28.9)], 
respectively (Table 2). By region (Table 3, 
Figure 1), the median sum of inorganic 
and methylated arsenic species was higher 
in Arizona (12.5 µg/g), intermediate in the 
Dakotas (9.1 µg/g), and lower in Oklahoma 
(4.4 µg/g). After adjustment for sex, age, body 
mass index, smoking, and alcohol use, par-
ticipants in Oklahoma and the Dakotas had 
approximately 80% and 29% lower urine 
concentrations, respectively, for the sum of 
inorganic and methylated arsenic species com-
pared with participants in Arizona (Table 4), 
although the differences were statistically sig-
nificant only for Oklahoma compared with 
Arizona. After multivariable adjustment, study 
region was the only statistically significant 
determinant of the sum of inorganic and meth-
ylated species at baseline (Table 4).
The sum of inorganic and methylated 
arsenic species remained relatively similar over 
10 years of follow-up (Table 2, Figure 1). The 
ICC for the sum of inorganic and methylated 
species was 0.80, with little difference across 
regions (Figure 1). After multivariable adjust-
ment, the average annual ratio over the 10-year 
follow-up was 1.23 [95% confidence interval 
(CI), 0.92–1.64], with no difference by partici-
pant characteristics (data not shown).
Arsenic excretion pattern. The means 
(± SDs) for %iAs, %MA, and %DMA over the 
sum of inorganic and methylated species at base-
line (visit 1) were 10.6 ± 5.2%, 18.4 ± 5.4%, 
and 70.9 ± 10.0%, respectively (Table 1). By 
region (Table 3, Figure 2), the mean %MA over 
the sum of inorganic and methylated arsenic 
species was lower in Oklahoma (15.4%) com-
pared with Arizona (19.4%) and the Dakotas 
(20.5%). After multivariable adjustment, mean 
%MA was 6.0% (95% CI, 3.8–8.2%) point 
increased in men compared with women, 
and –3.4% (95% CI, –6.1 to –0.7%) point 
decreased in participants in Oklahoma com-
pared with Arizona (Table 5).
The percentage distribution of arsenic spe-
cies remained relatively similar over 10 years of 
follow-up (Table 2, Figure 2). The overall ICCs 
for %iAs, %MA, and %DMA were 0.64, 0.80, 
and 0.77, respectively, with little difference 
across regions. After multivariable adjustment, 
the average annual change over the 10-year 
follow-up in %MA over the sum of inorganic 
and methylated species was –0.7% (95% CI, 
–1.5 to 0.2%), with no difference by partici-
pant characteristic (data not shown).
Discussion
This study quantified for the first time individual 
biomarkers of arsenic exposure and metabolism, 
as assessed in urine, in American Indian popula-
tions from Arizona, Oklahoma, and the Dakotas 
over a 10-year period. Total urine arsenic and the 
sum of inorganic and methylated arsenic species 
concentrations were higher in Arizona, interme-
diate (but high in some samples) in the Dakotas, 
and lower in Oklahoma, as expected based on 
data on arsenic in groundwater (Focazio et al. 
2000). For the sum of inorganic and methy-
lated compounds, four samples (two in Arizona 
and two in the Dakotas) exceeded 35 µg/g 
creatinine, a safety standard used to monitor 
inorganic arsenic exposure in occupational set-
tings (American Conference of Governmental 
Industrial Hygienists 2004). Arsenobetaine con-
centrations, related to seafood intake, were low 
compared with those in the U.S. general popula-
tion (Caldwell et al. 2009), reflecting low seafood 
intake in the study communities. The constancy 
in urine arsenic concentrations in three urine 
samples collected over a 10-year period (1989–
1999) is consistent with previous studies measur-
ing arsenic in private and public drinking water 
systems over long periods of time (Karagas et al. 
2001; Ryan et al. 2000; Steinmaus et al. 2005c) 
and support the observation that arsenic levels in 
drinking water are stable in the absence of public 
health interventions or changes in water sources. 
Our data also demonstrate the feasibility of using 
long-term stored urine samples for determining 
arsenic species in population-based studies.
The three Strong Heart Study visits were 
conducted between 1989 and 1999, before the 
Table 4. Baseline ratio (95% CI) of geometric means for the sum of inorganic and methylated arsenic 
  species in urine over time and by baseline participant characteristics.
Characteristic No.
Urine arsenic 
geometric mean 
(95% CI)
Crude ratio 
(95% CI)
Adjusted ratio 
(95% CI)a
Region
Arizona 20 11.2 (8.9–14.2) 1.00 (reference) 1.00 (reference)
Oklahoma 20 4.8 (3.9–5.8) 0.42 (0.28–0.63) 0.20 (0.07–0.55)
Dakotas 20 9.0 (5.7–14.0) 0.75 (0.50–1.12) 0.71 (0.25–2.04)
Sex
Female 34 7.7 (5.8–10.2) 1.00 (reference) 1.00 (reference)
Male 26 8.0 (6.0–10.7) 1.03 (0.71–1.51) 0.79 (0.35–1.80)
Age (years)
45–54 35 8.2 (6.5–10.3) 1.00 (reference) 1.00 (reference)
55–75 25 7.4 (5.2–10.6) 0.83 (0.57–1.22) 0.92 (0.39–2.20)
Body mass index
< 30 kg/m2 24 6.7 (5.1–8.9) 1.00 (reference) 1.00 (reference)
≥ 30  36 8.7 (6.6–11.4) 1.23 (0.84–1.80) 1.58 (0.69–3.65)
Smoking
Never 18 5.4 (4.0–7.3) 1.00 (reference) 1.00 (reference)
Former 19 10.8 (7.3–15.9) 1.99 (1.27–3.13) 2.69 (0.90–8.02)
Current 23 8.1 (5.9–11.0) 1.50 (0.97–2.31) 1.28 (0.39–4.22)
Alcohol
Never 9 5.0 (3.3–7.5) 1.00 (reference) 1.00 (reference)
Former 23 8.7 (6.2–12.0) 1.80 (1.03–3.15) 1.60 (0.42–6.11)
Current 28 8.4 (6.2–11.3) 1.71 (0.98–2.99) 2.47 (0.65–9.30)
aAdjusted for region, sex, age, body mass index, smoking, and alcohol.
Figure 2. Percentage of MA over the sum of inorganic and methylated species by study visit and region: (A) Arizona, (B) Oklahoma, (C) Dakotas. Blue lines con-
nect the levels for each participant; black lines represent the mean for each region. 
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U.S. EPA established the new arsenic maximum 
contaminant level in drinking water (10 µg/L). 
Data from public water systems in the states 
where the Strong Heart Study was conducted 
show that arsenic was higher in Arizona (coun-
ty-level 95th percentile, 20.5 µg/L) compared 
with Oklahoma (county-level 95th percentile, 
2.0 µg/L) and North and South Dakota (coun-
ty-level 95th percentile, 4.0 µg/L) (Focazio et al. 
2000). In the Strong Heart Study communi-
ties, arsenic concentrations measured in public 
drinking water systems in the 1990s and 2000s 
ranged from < 10 to 61 µg/L in Arizona and 
from < 1 to > 21 µg/L in North and South 
Dakota (no data are available for the Oklahoma 
communities, but levels were expected to be 
< 10 µg/L). Many participants in the Strong 
Heart Study rely upon private wells for water. 
Private wells do not need to comply with the 
U.S. EPA arsenic standard, and the water arse-
nic concentrations in many of them exceed 
10 µg/L, particularly in the western states 
(George et al. 2006; Steinmaus et al. 2005c).
Urine arsenic concentrations in participants 
from Oklahoma were comparable with those for 
a representative sample of U.S. adults (median 
total urine arsenic in participants with arseno-
betaine below the limit of detection, 3.4 µg/L) 
(Navas-Acien et al. 2008), reflecting generally 
low water arsenic concentrations (< 10 µg/L) 
in the United States. Urine arsenic concentra-
tions for participants from the Dakotas and 
in particular from Arizona were substantially 
higher, comparable to urine concentrations in 
populations in Nevada, California (Steinmaus 
et al. 2005a), and Central Europe (Lindberg 
et al. 2006) exposed to moderately high arse-
nic in drinking water (~ 10 to > 50 µg/L) but 
much lower than urine concentrations in popu-
lations in Taiwan (Hsueh et al. 2003), Chile 
(Hopenhayn-Rich et al. 1996a), or Bangladesh 
(Chen et al. 2007; Kile et al. 2009), where 
drinking-water arsenic concentrations often 
exceeds 100 µg/L.
Because arsenic metabolism is thought to 
play a major role in inorganic arsenic toxicity, 
there is substantial interest in understanding the 
distribution and main determinants of arsenic 
species in urine. The distribution and interin-
dividual variability of urine arsenic species in 
Strong Heart Study participants were compara-
ble with those reported in other human popula-
tions (Chiou et al. 1997; Del Razo et al. 1997; 
Hopenhayn-Rich et al. 1996b; Vahter 2000). 
Studies conducted in Argentina (Concha et al. 
2002) and Chile (Steinmaus et al. 2005b) pre-
viously showed a fairly constant within-person 
urine arsenic excretion pattern up to 1 year of 
follow-up. In our study, we extend this observa-
tion to 10 years, providing additional support 
for genetic factors influencing interindividual 
differences in arsenic metabolism (Hopenhayn-
Rich et al. 1996a; Loffredo et al. 2003; Vahter 
2000, 2002). Contrary to our study in the 
United States and previous studies in Argentina 
(Concha et al. 2002) and Chile (Steinmaus 
et al. 2005b), a recent study from Bangladesh 
measured low within-person reproducibility for 
%MA over a 2-year period (Kile et al. 2009). 
Similar to studies in the United States 
(Steinmaus et al. 2005a), Europe (Lindberg et al. 
2006), Chile (Hopenhayn-Rich et al. 1996b), 
Taiwan (Hsueh et al. 2003), and Bangladesh 
(Kile et al. 2009; Lindberg et al. 2008), men in 
our study had higher %MA in urine than did 
women. Some studies have also reported unad-
justed associations of smoking and alcohol with 
higher %MA in urine (Hopenhayn-Rich et al. 
1996a; Hsueh et al. 2003). In our study, after 
adjustment for sex, age, region, and body mass 
index, smoking and alcohol were not statistically 
associated with higher %MA, although our sam-
ple size was small. After adjustment for sex and 
other variables, participants in the Dakotas had 
a lower %MA concentration in urine compared 
with participants in Arizona or Oklahoma. The 
genetic determinants and health implications 
of differences in urine arsenic excretion patterns 
across study regions require further investigation.
Strengths of this study include the avail-
ability of repeated urine samples and the quality 
of the study measures. The Strong Heart Study 
used a standardized protocol for the recruitment 
of study participants, interviews, physical exam-
inations, and collection and storage of urine 
samples (Lee et al. 1990; Strong Heart Study 
2008). Some limitations include the relatively 
small sample size, the use of spot urine samples, 
the relatively high limit of quantification for 
arsenate, the storage of urine samples for > 10 
years, and the difficulty in directly evaluating the 
impact of time of freezer storage. The long-term 
stability of inorganic arsenic, MA, DMA, and 
arsenobetaine in stored urine samples has been 
evaluated for a 6- to 8-month period (Chen 
et al. 2002; Feldmann et al. 1999) and is further 
supported by the findings of our study. Arsenic 
species such as methylarsonite [MA(III)] and 
dimethylarsinite [DMA(III)], however, tend 
to quickly convert to their corresponding pen-
tavalent forms (MA and DMA) (Raml et al. 
2007; Steinmaus et al. 2005b) and could not 
be measured. Arsenite and arsenate generally 
interconvert in urine depending on handling 
and storage conditions, and the sum of the two 
is generally used to measure inorganic arsenic in 
urine. In our study, to deal with data missing 
due to a relatively high limit of quantification 
for arsenate, we imputed arsenite and arsenate 
concentrations below the limit of quantification 
using total arsenic as an explanatory variable. 
In an alternative approach, all arsenate could 
have been reduced to arsenite (or all arsenite 
could have been oxidized to arsenate) before 
laboratory analysis to provide a stable measure 
of inorganic arsenic in urine. Overall, although 
arsenic-related health outcomes could not be 
assessed because of the limited sample size, our 
study supports the feasibility of using long-term 
stored urine samples for measuring arsenic expo-
sure and metabolism in population-based stud-
ies such as the Strong Heart Study.
Arsenic in drinking water continues to be 
a public health problem in the United States, 
affecting several millions of Americans who live 
in small communities and rural areas, partly 
because private wells are not covered by the 
U.S. EPA maximum contaminant level, but also 
because of insufficient financial resources and 
public health infrastructure to ensure compliance 
with the arsenic standard in small communities. 
The well-established carcinogenic effect of arsenic 
(International Agency for Research on Cancer 
2004; National Toxicology Program 2002), and 
Table 5. Baseline difference (95% CI) in %MA over the sum of inorganic and mehtylated species.
Characteristic No.
%MA (baseline 
mean ± SD)
Crude difference 
(95% CI)
Adjusted difference 
(95% CI)a
Region
Arizona 20 19.4 ± 5.8 0.0 (reference) 0.0 (reference)
Oklahoma 20 15.4 ± 5.2 –3.5 (–6.8 to –0.3) –3.4 (–6.1 to –0.7)
Dakotas 20 20.5 ± 5.4 1.3 (–1.9 to 4.5) –0.3 (–3.1 to 2.5)
Sex
Female 34 22.6 ± 5.1 0.0 (reference) 0.0 (reference)
Male 26 15.2 ± 3.9 6.9 (4.6 to 9.1) 6.0 (3.8 to 8.2)
Age (years)
45–54 35 19.2 ± 6.1 0.0 (reference) 0.0 (reference)
55–75 25 17.3 ± 5.2 –1.6 (–4.4 to 1.2) –0.1 (–2.5 to 2.2)
Body mass index
<30 kg/m2 24 19.9 ± 5.9 0.0 (reference) 0.0 (reference)
≥ 30  36 17.4 ± 5.5 –2.6 (–5.4 to 0.2) –1.0 (–3.2 to 1.3)
Smoking
Never 18 15.8 ± 5.2 0.0 (reference) 0.0 (reference)
Former 19 16.9 ± 4.8 1.0 (–2.3 to 4.2) –1.6 (–4.5 to 1.3)
Current 23 21.8 ± 5.5 5.3 (2.2 to 8.5) 1.7 (–1.5 to 4.9)
Alcohol
Never 9 14.6 ± 4.0 0.0 (reference) 0.0 (reference)
Former 23 18.2 ± 5.5 2.8 (–1.4 to 6.9) 0.0 (–3.6 to 3.5)
Current 28 19.8 ± 6.0 4.7 (0.6 to 8.7) 0.4 (–3.1 to 4.0)
aAdjusted for region, sex, age, body mass index, smoking, and alcohol.Urine arsenic over a 10-year period
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evidence indicating a potential role of arsenic 
on cardiovascular disease and diabetes (Navas-
Acien et al. 2005, 2006; States et al. 2009; Yuan 
et al. 2007) highlight the importance of ensuring 
arsenic levels below the U.S. EPA maximum 
contaminant level in all water supply systems, 
including those serving small communities.
Conclusions
This study found low to moderate inorganic 
arsenic exposure and long-term constancy in 
urine arsenic concentrations and excretion pat-
terns among American Indians from Arizona, 
Oklahoma, and the Dakotas who participated 
in a large population-based prospective cohort 
study. In communities with stable environmen-
tal exposure to inorganic arsenic and with rela-
tively low fish intake, our study showed that a 
single determination of urine arsenic and its 
species provides a useful biomarker of ongo-
ing arsenic exposure and of individual arsenic 
metabolism. Additional research is needed to 
further characterize the genetic and environmen-
tal determinants of arsenic metabolism and the 
health impact of arsenic exposure and metabo-
lism, including cardiovascular disease and diabe-
tes, in populations exposed to low and moderate 
levels of inorganic arsenic in drinking water.
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